Addressing the Efficacy of Perioperative Octreotide for Carcinoid Crisis in Patients with Neuroendocrine Tumors
Rodney Pommier, MD, FACS, professor of surgery, division of surgical oncology, school of medicine, Oregon Health & Science University, addresses the questions surrounding the efficacy of perioperative octreotide treatment for patients experiencing a carcinoid crisis.
Pharmacy Times interviewed Rodney Pommier, MD, FACS, professor of surgery, division of surgical oncology, school of medicine, Oregon Health & Science University, on his presentation at the 2021 NANETS Multidisciplinary Neuroendocrine Tumors (NETs) Medical Virtual Symposium discussing a prospective study of carcinoid crisis with no perioperative octreotide.
During the interview, Pommier addressed the questions surrounding the efficacy of perioperative octreotide treatment for patients with NETs experiencing a carcinoid crisis and why these questions were important to investigate.
